Todd McDevitt, PhD is a Senior Investigator at the Gladstone Institutes, a Professor in the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco (UCSF), and Director of the Bioengineering Graduate Program at UCSF. The primary objective of Dr. McDevitt’s research is to engineer stem cell technologies capable of directing differentiation and morphogenesis more effectively in order to create new models of development and disease, novel drug screening platforms, and regenerative medicine therapies. The McDevitt laboratory has been a leader in the development of novel 3D suspension culture platforms for stem cell morphogenesis and scalable biomanufacturing. In addition to stem cell tissue engineering efforts, his research group has also innovated several parallel approaches to develop stem cell-derived molecular therapies for immunomodulation, tissue repair and regeneration, and anti-aging applications. Dr. McDevitt has received several honors and awards, including a New Investigator Award from the American Heart Association, the Society for Biomaterials Young Investigator Award, a California Institute for Regenerative Medicine (CIRM) Research Leadership Award, recognition as one of the “40 Under 40” by Georgia Trend magazine (2013), and induction into the American Institute of Medical and Biological Engineering (AIMBE) College of Fellows. Dr. McDevitt graduated cum laude with a Bachelor of Science in Engineering (BSE) from Duke University double majoring in Biomedical and Electrical Engineering, received his PhD in Bioengineering from the University of Washington, and conducted post-doctoral research in the Department of Pathology at the University of Washington.
Senior Investigator, Gladstone Institute of Cardiovascular Diseaser
Professor, Dept. of Bioengineering & Therapeutic Sciences, UCSF